Tag archive for ‘DexaSite’
InSite Vision: DOUBle Trial Results are Disappointing-What Comes Next? (INSV.OB, $0.33)
Summary and Investment Thesis InSite Vision (INSV.OB) just reported that topline results for AzaSite Plus and DexaSite in the DOUBle trial were disappointing and failed to meet the primary endpoint of that trial. Clinical trials can fail because the drug(s) is ineffective, but they can also fail because of trial design and there are good […]
InSite Vision: Initiating Coverage on a Promising Company with a Robust Late Stage Product Portfolio
I have just published a new report and initiated coverage of InSite Vision (INSV, $0.30) with a Buy. The core technology of InSite Vision is its DuraSite drug delivery system that delivers drugs more effectively to the eye. The continual blinking of the eye can quickly wash out topical formulations and in order to retain […]